Tirzepatide (brand name Mounjaro) is a dual GLP-1 and GIP receptor agonist, primarily used for type 2 diabetes management and weight loss. It has shown superior weight loss effects compared to Semaglutide (Ozempic/Wegovy).

1. GLP-1 Receptor Activation (Glucagon-Like Peptide-1)
   • Increases insulin secretion to lower blood sugar.
   • Suppresses glucagon release, reducing blood sugar spikes.
   • Slows gastric emptying, increasing satiety and reducing food intake.

1. GIP Receptor Activation (Glucose-Dependent Insulinotropic Polypeptide)
   • Enhances insulin sensitivity, making the body more efficient at using glucose.
   • Works synergistically with GLP-1 to boost metabolic function.
   • May help preserve lean muscle mass during weight loss.

✅ Superior Weight Loss – Clinical trials show up to 22.5% body weight reduction, making it more effective than Semaglutide.
✅ Enhanced Blood Sugar Control – Lowers A1C levels significantly for diabetes management.
✅ Greater Appetite Suppression – Reduces hunger and cravings more effectively than GLP-1 agonists alone.
✅ Improved Fat Metabolism – Helps burn fat while preserving muscle mass.
✅ Cardiovascular Protection – Lowers blood pressure, cholesterol, and overall heart disease risk.
✅ Potential Longevity & Metabolic Health Benefits – May support anti-aging, neuroprotection, and inflammation reduction.